Reading path

How a Lab Discovery Becomes a Treatment

Most promising discoveries never reach a single patient, and this path walks you through the reasons why. You will follow a finding from the lab bench through target selection, preclinical testing, first-in-human trials, and manufacturing all the way to routine care. By the end you will be able to read any translational claim and judge honestly where it sits on that long road.

The path, step by step

1. 1 The Translation Gap: Why Good Research Rarely Becomes a Tool Clinicians Use

   5 min read

   Start here to see the whole problem at a glance: why strong research so rarely turns into a tool a clinician actually uses.

2. 2 The Two-Fold Bet: How Human Genetic Evidence Reshapes the Odds a Drug Target Succeeds

   4 min read

   The journey really begins with target choice, and this shows how human genetic evidence changes the odds a drug target will ever succeed.

3. 3 Why Most Preclinical Breakthroughs Never Reach Patients: Rigor and Reproducibility

   5 min read

   Before anything reaches a person it must survive the lab, and this explains why so many exciting preclinical results collapse when others try to repeat them.

4. 4 Can a Chip Replace a Mouse? The Evidence Standards Behind Organ-on-Chip Systems

   5 min read

   Preclinical testing is changing, so this examines the evidence bar a new model like organ-on-chip must clear before its results can be trusted.

5. 5 The Valley of Death in Translational Research: Why Good Science Stalls

   5 min read

   Here the path names the chasm where good science stalls between promising preclinical work and the first human study, and why funding and structure decide who crosses it.

6. 6 How a Biotech Idea Moves From the Lab to the Clinic

   5 min read

   With the obstacles in view, this lays out the actual mechanics of moving a candidate out of the lab and into first-in-human testing.

7. 7 Biomarker Qualification Explained: Why a Measurement Has to Earn a Defined Use

   5 min read

   Biomarkers guide much of modern development, so this teaches how a measurement earns one defined, trustworthy use rather than being treated as proof of everything.

8. 8 The First AI-Designed Drug Reached Phase 2a: What the Trial Actually Showed

   4 min read

   A concrete early-trial case lets you practice separating a genuine milestone from what a small phase 2a readout can and cannot establish.

9. 9 Manufacturing Is the Medicine: Why CMC and GMP Decide Whether a Cell or Gene Therapy Reaches Patients

   4 min read

   A therapy that works is still useless if it cannot be made reliably, and this shows why manufacturing, not the biology, is often the true rate-limiting step to reaching patients.

10. 10 Why Health-Technology Pilots Succeed and Then Fail to Scale

    5 min read

    The path closes on the last mile: why something that works in a pilot can still fail to become routine care, bringing you back to the translation gap with sharper eyes.

Each step is a full article on the Reading the Evidence blog.

Back to all reading paths